Revenue
2011
2012
2013
2014
2015
2022
2023
2024
2025
Provectus Biopharmaceuticals, Inc. (PVCT)
Price$0.0600Cached quote
Net income
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2011
2012
2013
2014
2015
2017
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $336,108 | $617,140 | $557,710 | $989,042 | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | — | — | — | — | — | — | — | — |
| Research & development | $1.9M | $2.1M | $1.7M | $2.4M | $2.6M | $2.8M | $4.0M | $4.7M | $8.2M | $8.2M | $11.4M | $5.8M | $3.6M | $5.0M | $8.8M | $8.4M | $4.9M | — | — | — | — | — | — |
| Operating expenses | $5.6M | $5.1M | $3.5M | $4.4M | $4.7M | $5.0M | $6.3M | $8.1M | — | — | — | — | — | — | $21.4M | — | — | — | — | — | — | — | — |
| Operating income | −$5.3M | −$4.5M | −$2.9M | −$3.4M | −$4.7M | −$5.0M | −$6.3M | −$8.1M | −$13.3M | −$24.5M | −$24.7M | −$12.6M | −$13.0M | −$14.3M | −$21.4M | −$20.7M | −$12.3M | — | — | — | — | — | — |
| Operating margin | −1,575.32% | −734.42% | −520.21% | −346.59% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$5.3M | −$4.5M | −$2.9M | −$3.4M | −$4.7M | −$4.7M | −$5.6M | −$7.4M | −$12.6M | −$23.8M | −$24.0M | −$12.0M | −$12.4M | −$13.7M | −$20.8M | −$20.0M | −$12.3M | — | — | — | — | — | — |
| EBITDA margin | −1,574.76% | −733.26% | −518.61% | −345.49% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$5.4M | −$4.7M | −$3.1M | −$3.6M | −$5.5M | −$6.7M | −$6.9M | −$8.2M | −$13.5M | −$24.4M | −$24.5M | −$10.2M | −$27.7M | −$12.6M | −$19.4M | −$18.6M | −$12.3M | −$10.3M | −$10.0M | −$8.9M | −$11.8M | −$4.3M | −$3.2M |
| Net profit margin | −1,615.81% | −766.85% | −556.16% | −359.41% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.02 | -$0.02 | -$0.04 | -$0.12 | -$0.13 | -$0.06 | -$0.22 | -$0.11 | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.02 | -$0.02 | -$0.04 | -$0.12 | -$0.13 | -$0.06 | -$0.22 | -$0.11 | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
≈4.40%of listed shares
Morris Jeffrey Allen18.5M shares · Aug 12, 2024
View holders
| Holder | % owned |
|---|---|
Morris Jeffrey Allen | ≈4.40%18.5M shares |
HOME FEDERAL BANK OF TENNESSEE | 0.02%100K shares |
Atlas Wealth LLC | <0.01%19.62K shares |
Financial Symmetry Inc | <0.01%10.19K shares |
HUNTINGTON NATIONAL BANK | <0.01%1 shares |
Percentages use 420.28M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 9, 2026Form 4 | Pershing EdwardCEO | BuySeries D-1 Convertible Preferred Stock · derivative | 34.9K | $2.86 | $99.9K | 2.61M |
| Nov 22, 2024Form 4 | Pershing EdwardCEO | BuySeries D-1 Convertible Preferred Stock · derivative | 80.4K | $2.86 | $229.8K | 1.69M |